Eyenovia Secures $5.14 Million Through Public Offering
Eyenovia Announces $5.14 Million Public Offering
Eyenovia, Inc. (“Eyenovia” or the “Company”) (NASDAQ: EYEN), a commercial-stage ophthalmic company, has agreed to sell 12,850,000 shares of common stock at a price per share of $0.40.
Details of the Offering
The closing of the Offering is expected to occur soon, subject to the satisfaction of customary closing conditions. All the securities in the Offering are being sold by Eyenovia, with Dawson James Securities, Inc. acting as the placement agent. The gross proceeds from this Offering are estimated to be approximately $5.14 million, before deducting fees and other expenses.
Planned Use of Proceeds
Eyenovia intends to use the net proceeds from the Offering to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study, as well as for working capital and general corporate purposes.
Securities Registration
The securities being offered are pursuant to a previously filed shelf registration statement on Form S-3, effective as of December 23, 2021. The Offering may be made only by means of a prospectus supplement and accompanying prospectus.
Contact for Prospectus
Prospectus information can be obtained by contacting Dawson James Securities, Inc., or by telephone or email as specified.
About Eyenovia, Inc.
Eyenovia, Inc. specializes in ophthalmic technology, commercializing Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension, and advancing the Optejet® device for pediatric progressive myopia. For more information, please visit Eyenovia.com.
Contact Information
Eyenovia Contact:
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com
Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com
Frequently Asked Questions
What is the total amount raised in the public offering?
The public offering is expected to raise approximately $5.14 million.
What will the proceeds from the offering be used for?
The proceeds will fund commercialization activities, a clinical study, and for working capital and general corporate purposes.
Who is acting as the placement agent for the offering?
Dawson James Securities, Inc. is the placement agent for the offering.
When is the closing date for the offering?
The closing date is expected to be soon, subject to customary closing conditions.
What products are associated with Eyenovia, Inc.?
Eyenovia, Inc. is commercializing Mydcombi and Clobetasol Propionate Ophthalmic Suspension, among other developments.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Tesla Celebrates Exporting One Millionth Vehicle from Shanghai
- Kamala Harris Secures $55 Million to Boost Presidential Bid
- Accenture’s Upgraded Outlook Supports Growth Through FY26
- Sequentia Biotech Raises €10 Million to Enhance Bioinformatics
- RD Technologies Raises $7.8 Million to Enhance Web3 Solutions
- SIFI Secures European Patent and Launches AKANTIOR® in Germany
- NNIT A/S Secures Major Contract to Enhance SAP Solutions
- Syensqo Initiates Significant Share Buyback Program Worth €300 Million
- Modalis Therapeutics Secures FDA RPD Designation for MDL-101
- MSTX ETF Breaks $400 Million Barrier Amid Growing Interest
Recent Articles
- Geospatial Analytics Market Growth and Opportunities Ahead
- Cryogenic Tank Market Growth and Key Insights
- Exploring Growth in the Intellectual Property Management Software Market
- Compression Therapy Market to Hit $7.86 Billion by 2032
- Breast Implants Market Growth Forecast to $5.34 Billion
- Power Rental Market Growth Projections by SkyQuest
- Military Robots Market Growth Forecast by SkyQuest Technology
- Last Mile Delivery Market Growth at 8.5% CAGR
- Management Changes at Liven AS Subsidiaries
- Monthly Distribution Announcement for Quadravest ETF
- AMD's 2023-24 Corporate Responsibility Report Highlights
- ibex Receives Gold Globee Award for Innovation in CX
- GeoVax Lab CEO to Speak at Tribe Public Webinar
- GDEV Implements One-For-Ten Reverse Share Split
- Scilex Holding Company to Receive New Patent for ELYXYB Treatment
- Firefly Neuroscience Partners with Neurology Consultants for Patient Care
- Credo Technology Group to Present at Key Investor Conference
- MKS Instruments to Speak at Citi’s Global TMT Conference
- 2024 Luxury Resale Insights from The RealReal
- Sharad Agarwal Appointed CEO of Sify Infinit Spaces Limited
- BANK of Greenland Reports Strong H1 2024 Results
- IR-MED Honored with Best Health Tech Company Award
- McGraw Hill Unveils New AI Tools for Education
- Nokia and Axiom Space Collaborate for Lunar Connectivity
- Advanced Dental Treatments by Prestige Dentistry
- Silicon Photomultiplier Market Growth Insights and Trends
- Bioinsecticides Market Growth Driven by Eco-Friendly Solutions
- Bollinger Motors Launches Production of Class 4 EV Trucks
- Amotai and NMSDC Collaborate for Minority Entrepreneurs
- Gordon Brothers Appoints Kasey Fagan for Midwest Growth
- Multi-Cancer Early Detection Market Growth Insights
- Onychomycosis Market Growth Projection by Polaris Research
- Biofuel Additives Market Growth to USD 32.39 Billion
- Mediaocean's 2024 H2 Report: CTV Leads Marketing Trends
- AdRoll Insights Show Stabilizing Advertising Trends
- Siili Solutions Plc Reports Managers' Transactions
- La Rosa Expands with New Brokerage Acquisition
- Oragenics Advances ONP-002 for Concussion Treatment
- Disclosure from Rathbones Group on Balanced Commercial Trust
- LPL Financial Welcomes New Advisors from Academy Financial and PFG Advisors
- Key Position Disclosure for Keywords Studios Plc
- Salinas Achieves Blue Zones Community Certification
- Atossa and Quantum Leap Collaborate on Breast Cancer Trial
- iCoreConnect and DSO MarketWatch Partnership Boosts Dental Services
- Bridgeline Digital Launches HawkSearch Multi-Site Management
- Intelligent Bio Solutions Inc. Hits 1,000 Fingerprinting Readers
- HealthEquity Launches HSA Week 2024 with New Resources
- ICU Medical Investor Conference Attendance Announcement
- KULR Technology Leadership Transition and Office Relocation
- PetMed Express to Join Morgan Stanley Global Healthcare Event